# US 2022/0054647 A1 · Sstr-targeted conjugates and particles and formulations thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0054647 A1
- Document ID: US20220054647A1
- Status: Published application
- Kind: A1
- Application number: 17/518,794
- Filed: 2021-11-04
- Published: 2022-02-24
- Earliest claimed: 2016-10-28
- Assignees: Tarveda Therapeutics, Inc.
- Applicants: Tarveda Therapeutics, Inc.
- Inventors: Rajesh R. Shinde; Rossitza G. Alargova; Patrick Lim Soo; Beata Sweryda-Krawiec; Leila Alland; Christopher Sears
- Web page: https://patentgrep.com/patent/US20220054647A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 31/537: spiro-condensed or forming part of bridged ring systems
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

## Claims

### Claim 1

A pharmaceutical composition comprising a conjugate and at least one excipient, wherein the conjugate comprises an active agent coupled to a somatostatin receptor (SSTR) targeting moiety by a linker, wherein the active agent is mertansine (DM1).

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the conjugate has a structure of:

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the conjugate has a concentration of between about 2.0-about 5.0 mg/mL.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the conjugate has a concentration of about 2.5 mg/mL.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, wherein the pH of the composition is between about 4.0 to about 5.0.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the pH of the composition is between about 4.0 to about 4.8.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the pH of the composition is about 4.0.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the composition comprises acetate buffer.

### Claim 9 (depends on 2)

The pharmaceutical composition of claim 2, wherein the composition further comprises mannitol.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the mannitol has a concentration of between about 25 to about 75 mg/mL.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the mannitol has a concentration of about 50 mg/mL.

### Claim 12 (depends on 2)

The pharmaceutical composition of claim 2, wherein the composition further comprises polyoxyl 15 hydroxystearate.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the polyoxyl 15 hydroxystearate has a concentration of between about 10 to about 50 mg/mL.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the polyoxyl 15 hydroxystearate has a concentration of about 20 mg/mL.

### Claim 15

A method of treating tumor of a subject, comprising conducting a Somatostatin Analog Radioisotope Imaging (SARI) scanning on the subject and administering a pharmaceutical composition comprising a conjugate and at least one excipient to the subject if the SARI result is positive, wherein the conjugate comprises an active agent coupled to a somatostatin receptor (SSTR) targeting moiety by a linker, wherein the active agent is mertansine (DM1).

### Claim 16 (depends on 15)

The method of claim 15, wherein the SARI scanning comprises using a radioisotope linked to a somatostatin analog.

### Claim 17 (depends on 16)

The method of claim 16, wherein the radioisotope comprises 111In, 68Ga, or 99mTc.

### Claim 18 (depends on 16)

The method of claim 16, wherein the SARI scanning comprises using a 111In pentetreotide.

### Claim 19 (depends on 16)

The method of claim 16, wherein the SARI scanning comprises using 68Ga derivatives of somatostatin analogs.

### Claim 20 (depends on 19)

The method of claim 19, wherein the 68Ga derivatives of somatostatin analogs comprise 68Ga-DOTATATE or 68Ga-DOTATOC.

### Claim 21 (depends on 16)

The method of claim 16, wherein the SARI scanning is conducted with single-photon emission computed tomography (SPECT) or concurrent positron emission tomography (PET) and Computed tomography (CT).

### Claim 22 (depends on 19)

The method of claim 19, further comprising administering at least one additional active agent.

### Claim 23 (depends on 22)

The method of claim 22, wherein the additional active agent is a drug for treating nausea, vomiting, diarrhea, constipation, anemia, neutropenia, or a somatostatin analog.

### Claim 24 (depends on 15)

The method of claim 15, wherein the tumor is a neuroendocrine tumor (NET).

### Claim 25 (depends on 24)

The method of claim 24, wherein the tumor selected from the group consisting of gastroenteropancreatic (GEP), lung, prostate, and thymus neuroendocrine tumor.

### Claim 26 (depends on 25)

The method of claim 25, wherein the tumor is small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung.

### Claim 27 (depends on 15)

The method of claim 15, wherein the conjugate is Conjugate 57.

### Claim 28 (depends on 27)

The method of claim 27, wherein the dosage of Conjugate 57 is at least about 0.016 mg/kg.

### Claim 29 (depends on 27)

The method of claim 27, wherein the dosage of Conjugate 57 is at least about 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, 42 mg, or 48 mg.

### Claim 30 (depends on 27)

The method of claim 27, wherein the dosage of Conjugate 57 is about 25 mg.
